Objectives. The aim of this study was to extend the description of the epidemiologic pattern of human immunodeficiency virus (HIV)/tuberculosis (TB) coinfection from 1998 to 2007 in a high HIV/AIDS prevalence country. Design and Methods. This study utilized registry data to determine yearly TB incidence and HIV coinfection. Mortality rates for coinfected patients were calculated and compared with patients receiving highly active antiretroviral therapy (HAART). Results. From a TB population of 2010 registered patients, data was collected on the 466 patients with HIV/TB coinfection. The coinfection rate was found to be 23.6% for the study period. Patients on HAART were twice as likely to survive. Discussion and Conclusions. The incidence of TB and HIV/TB coinfection rates continues to be major challenges in the developing world. Demographic, socioeconomic trends as well as risk factors remain unchanged. Increased HIV screening and HAART coverage offers hope for the future.
Introduction
Human immunodeficiency virus (HIV)-associated tuberculosis (TB) is a major public health challenge explicitly referred to in the Millennium Development Goals. 1 Approximately 2 billion people or two thirds of the world population are infected with the tuberculosis bacilli 2 and about 33 million were living with HIV by the end of 2007. 3 Trinidad and Tobago is the southernmost island in the Caribbean archipelago, a region ranked second to sub-Saharan Africa in the global burden of HIV/AIDS. Although TB is one disease, and Mycobacterium tuberculosis alone its cause, 4 epidemiological patterns have emerged of which HIV-related disease is the dominant pattern. 4 In countries with the highest HIV prevalence, more than 75% of cases of TB are HIV-associated. 4 In 2005, the incidence of TB in Trinidad and Tobago was estimated to be 8.9 per 100 000 per year. 5 The Pan American Health Organization (PAHO) reported a 7.5% increase of new cases of TB during the period 1995-1999. 6 Furthermore, TB increased from 47.8% to 54.8% among the age group 15 to 44 years, with the highest percentage of new cases (23.5%) occurring among the age group 35 to 44. 6 The percentage of new cases coinfected with HIV in 1995 was 32.5%, which increased to 39.1% in 1999. 7 Furthermore, the United Nations General Assembly Special Session (UNGASS) Country Progress Report for Trinidad and Tobago showed that the incidence of HIV/TB coinfection increased from 24% in 2004 to 29% in 2006. 8 Treatment outcomes for HIV/TB in our setting have been disappointing. From 2004 to 2005, the number of patients cured decreased from 20.6% to 11%, while the number of patients who died increased from 29.4% to 42%. 8 The use of highly active antiretroviral therapy (HAART) in TB-endemic areas has been associated with a more than 80% reduction in the incidence of HIV-associated TB. The protective effect of HAART was seen at all stages of HIV disease but was greatest in symptomatic patients and those with advanced disease. 9, 10 In addition, several observational studies reported that the concurrent use of HAART and TB treatment in coinfected patients resulted in reduced mortality. 11 Tuberculosis treatment consists of a 6-month treatment regimen. In the first phase of 2 months duration, all patients are admitted to hospital and administered isoniazid, rifampicin, pyrazinamide, and ethambutol. In the second phase, patients are treated with rifampicin and isoniazid. Highly active antiretroviral therapy for HIV infection was introduced by the Ministry of Health (MOH) in Trinidad in April 2002. 12 There were groups of patients, those treated with existing therapies and those treated with HAART.
The aim of this study is to extend the description of the epidemiologic pattern of HIV/TB coinfection from 1998 to 2007, in a high HIV/AIDS prevalence country. In addition, we examined the effect of the introduction of HAART on HIV/TB coinfections, and compared it with existing therapy used.
Methodology
We used a retrospective cohort study design. The primary research centre is the Caura Chest Hospital. This center was chosen because it is the national treatment center for all TB patients managed within the public health care system and would account for the largest number of cases. The national TB register was used to validate all cases and identify additional cases. Thus, a database of all cases was created, which was used to locate and access medical records. The World Health Organization (WHO) definitions of TB and HIV were adopted. 13 Highly active antiretroviral therapy was defined using WHO criteria supported by guidelines published by the US Department of Health and Human Services. [14] [15] [16] In Trinidad and Tobago, efavirenz (EFV), lamivudine (3TC), and zidovudine (ZDV) are the specific agents used in HAART. The inclusion criteria for subjects were (1) a diagnosis of HIV/TB coinfection, and (2) patients receiving HAART. We excluded non-Trinidadian patients, patients who were treated for chest infections other than TB, patients presenting for multiple treatments of TB, and patients who defaulted from treatment previously.
All data were collected using a data collection instrument designed to collect data in sections specifically demographic data (age, gender), clinical profiles, treatment outcomes in patients receiving any form of treatment for HIV/TB coinfection including HAART, and CD4 counts. All medical records obtained were reviewed to extract the relevant data. All analyses were conducted using SPSS version 16. Ethical approval for the conduct of the study was obtained from the University of the West Indies ethics committee.
Results
The total number of TB cases for the period 1998-2007 was 2010, while the number with HIV/TB coinfection was 466 ( Table 1 ). The percentage of HIV/TB coinfection was 23.2, which is higher than the 15.4% reported in 2000 but less than the 26.4% reported in 1998. In 2007, the highest number of cases of TB (n ¼ 266) were recorded, which was marginally higher than 2006 (n ¼ 261). Additionally, 2007 also had the highest number of HIV/TB coinfection cases (69). In the first half of the decade, the number of cases averaged 43 per annum; however, in the latter half the average number of cases was 50 per annum, mainly as a result of the significantly larger number of cases seen in both 2006 and 2007. There were 3 times more male patients (355) than female (111) patients with HIV/TB coinfection (m:f, 3:1). The average age of HIV patients coinfected with TB was 40.2 years with the average age of males being 41.8 years and females 34.9 years. The 25 to 29 age group had the highest number of HIV/TB coinfection 327 (70%; Table 2 ).
The overall case fatality rate (CFR) among patients with HIV/TB coinfection was 64.6%. However, 1999 had the highest CFR (86.7%), which was 34% who were receiving HAART therapy. This represented a 50% reduction in mortality. Among all, the HIV/TB-coinfected patients for the period 1998 to 2007, 18.9% (n ¼ 88) were substance abusers and 7.1% (n ¼ 33) where prisoners. The proportion of deaths among substance abusers was 67% (n ¼ 35) and 56% (n ¼ 18) among prisoners.
In only 72 (15.5%) patients with HIV/TB coinfection, CD4 counts were available for analysis. The average CD4 count was 183 cells/ mm 3 , which ranged from as low as 3 cells/mm 3 to 1887 cells/mm 3 . The average CD4 count for patients who subsequently became sputum negative was 184 cells/ mm 3 , while the average CD4 count for those who died was significantly lower (157 cells/mm 3 , P < .05).
Discussion
There was an overall increase in the number of patients with HIV/TB coinfection over the decade 1998 to 2007. This finding parallels those of the UNGASS Country Progress Report for Trinidad and Tobago. 8 This is against the background of declining HIV infections between 2003 and 2006, confirming that TB continues to be the major opportunistic infection in our setting. Furthermore, the sustained occurrence of TB among non-HIV infected people suggests that there are several epidemiological patterns of TB transmission occurring simultaneously, which impacts adversely on strategies for TB control.
At the time the study ended, only 19.1% of new patients with HIV/TB coinfection were receiving HAART despite its adoption as a national policy intervention program in 2002 by the MOH. Treatment outcomes (cure vs death) for patients receiving HAART showed that 66% of patients were cured (smear-negative) compared to 31.5% who were still on existing therapy. Alarmingly, mortality rate among patients who were on HAART was 33.8% compared to 68.5% (odds ratio [OR] 4.2, P < .05) who were not on HAART. This finding urgently requires efforts to ensure that all HIV/TB-coinfected patients receive HAART, as it provides further evidence of the efficacy of HAART, which is consistent with findings reported both in South Africa and in Brazil. 9, 10 Similar to many other countries, 65.4% of patients were first diagnosed with TB and subsequently HIV. We therefore provide evidence in support of voluntary counseling and testing (VCT) programs recently introduced at all primary care centers in an attempt to improve screening. Early detection of HIV, treatment, and monitoring will affect positively on both HIV and TB control.
There was a high male/female ratio (3.2:1) of HIV/ TB coinfection, which was similarly reported by PAHO. 6 This finding may be explained by the greater risk-taking behaviors of male patients such the use of illicit drugs and casual unprotected sex practices.
Two high-risk groups identified for HIV/TB coinfection are prisoners and substance abusers. We specifically measured the proportion of these 2 groups and found in fact that drug abusers (18.9%) and prisoners (7.1%) were the 2 largest subgroup of patients with HIV/TB, a finding supported by PAHO. 7 The most common substances abused were found to be cocaine, marijuana, and alcohol, thus emphasizing the link between substance use and HIV and the need for continued drug interdiction methods as well as health promotional strategies. In addition, prison confinement is the ideal setting for both HIV and TB transmission, which requires specific interventions for prevention. The average CD4 count among the 72 patients with documented evidence of being tested was 183 cells/mm 3 . The average CD4 count for those cured (sputum negative) was 184 cells/mm 3 , while the average CD4 count for those who died was 157 cells/mm 3 . Ackah et al reported that the highest death rates occur in patients with the lowest CD4 count. 17 In those patients who had a CD4 count performed and also received HAART, the cure rate was 75%. Using hierarchical multiple regression analysis, both CD4 count and HAART together were significant predictors of being cured (R 2 ¼ .0665). This is against the background of a number of studies that support the use of antiretroviral therapy (ART) in all individuals with a CD4 count <350 cells/ mm 3 . [18] [19] [20] [21] [22] [23] [24] [25] [26] We therefore recommend CD4 counts for all patients with HIV/AIDS.
The major limitation of the study was that the 10year retrospective period offered challenges to the collection and compilation of the data particularly the retrieval of patient records from which most of the data was extracted. All medical records in this setting are handwritten in a hard copy format and stored manually.
In conclusion, we provide epidemiological evidence of the occurrence of TB in both HIV and non-HIV-infected people in Trinidad, one of the small islands of the Caribbean archipelago where HIV/ AIDS prevalence is ranked second to sub-Saharan Africa. Furthermore, we identified gaps in the care of both HIV-monoinfected and HIV/TB-coinfected patients emphasizing the difference between resource-limited countries and the developed world.
